Striatal Medium Spiny Neurons in Huntington's Disease
Striatal Medium Spiny Neurons in Huntington's Disease <div class="infobox infobox-cell">
Pathway / Mechanism Diagram
graph TD
A["HTT Gene: CAG Repeat Expansion"] --> B["Mutant Huntingtin (mHTT)"]
B --> C["Polyglutamine Aggregation"]
C --> D["Nuclear Inclusions"]
B --> E["Transcriptional Dysregulation"]
E --> F["BDNF Downregulation"]
F --> G["Striatal Neuron Vulnerability"]
B --> H["Mitochondrial Dysfunction"]
H --> I["Energy Deficit"]
B --> J["Impaired Autophagy"]
J --> K["Toxic Protein Accumulation"]
G --> L["Medium Spiny Neuron Death"]
I --> L
K --> L
L --> M["Chorea and Motor Symptoms"]
L --> N["Cognitive Decline"]
L --> O["Psychiatric Symptoms"]
style A fill:#ef5350,color:#e0e0e0
style L fill:#ef5350,color:#e0e0e0
style B fill:#5d4400,color:#e0e0e0
Introduction ...
Striatal Medium Spiny Neurons in Huntington's Disease
Striatal Medium Spiny Neurons in Huntington's Disease <div class="infobox infobox-cell">
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Introduction Striatal medium spiny [neurons](/entities/neurons) (MSNs) are the principal neurons of the striatum, comprising approximately 90-95% of all striatal neurons. These GABAergic projection neurons are the primary effectors of the basal ganglia motor loop, integrating excitatory cortical and thalamic inputs to modulate movement. In Huntington's disease (HD), MSNs are among the first neuronal populations to degenerate, leading to the characteristic choreiform movements, cognitive deficits, and psychiatric symptoms [1](https://doi.org/10.1016/j.tins.2020.08.008).
<!-- taxonomy-enrichment -->
<!-- multi-taxonomy-enrichment -->
Multi-Taxonomy Classification
Taxonomy Database Cross-References | Taxonomy | ID | Name / Label |
Morphology & Electrophysiology
Morphology : medium spiny neuron (source: Cell Ontology)Morphology can be inferred from Cell Ontology classification
External Database Links
[Cell Ontology (CL:1001474)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_1001474)
[OBO Foundry (CL:1001474)](http://purl.obolibrary.org/obo/CL_1001474)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[Human Cell Atlas](https://www.humancellatlas.org/)
Taxonomy & Classification | Database | ID | Name | Confidence |
External Database Links
[Cell Ontology (CL:1001474)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_1001474)
[OBO Foundry (CL:1001474)](http://purl.obolibrary.org/obo/CL_1001474)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
Anatomy and Morphology
Structural Characteristics MSNs possess distinctive morphological features [2](https://doi.org/10.1093/brain/awaa224):
Cell body : 10-20 μm diameter, medium-sizedDendrites : Highly branched, dense spine coverage (approximately 10,000 spines per neuron)Axon : Long, myelinated projection to globus pallidus and substantia nigraSpines : [Dendritic spines](/mechanisms/dendritic-spines) receive ~95% of excitatory synaptic inputTwo MSN Subtypes MSNs are divided into two populations based on projection target and neurochemical phenotype [3](https://doi.org/10.1016/j.neuron.2020.03.012):
| Feature | D1-MSNs (Direct Pathway) | D2-MSNs (Indirect Pathway) |Dopamine Receptor | D1R | D2R |Projection | Substantia nigra pars reticulata (SNr) | Globus pallidus externus (GPe) |Effect on Movement | Movement initiation | Movement suppression |Pathway | Direct | Indirect |Neuropeptide | Dynorphin | Enkephalin |
Molecular Characteristics
Dopamine Receptor Signaling
D1 receptors (DRD1) : Gs-coupled, increase cAMP, promote movementD2 receptors (DRD2) : Gi-coupled, decrease cAMP, inhibit movementIntracellular Signaling Pathways
cAMP/PKA pathway : Regulates neuronal excitabilityDARPP-32 : Amplifies dopamine signaling[mTOR](/mechanisms/mtor-signaling-pathway) pathway : Protein synthesis, synaptic plasticityERK/MAPK pathway : Gene expression, survivalMarker Genes
DRD1 : Direct pathway markerDRD2 : Indirect pathway markerPENK : Preproenkephalin (D2-MSNs)PDYN : Prodynorphin (D1-MSNs)RGS9 : Regulator of G-protein signalingNormal Function
Motor Control MSNs integrate information to modulate movement [1](https://doi.org/10.1016/j.tins.2020.08.008):
Direct pathway (D1-MSNs) : Facilitate movement by inhibiting SNr outputIndirect pathway (D2-MSNs) : Suppress competing movements via GPe
Reinforcement learning through reward prediction errors
Procedural memory formation
Habit encoding in sensorimotor striatum
Reward Processing
Integrate dopaminergic reward signals
Modulate goal-directed and habitual behaviors
Huntington's Disease Pathology
Early Vulnerability MSNs are selectively vulnerable in HD due to [2](https://doi.org/10.1093/brain/awaa224):
Direct pathway degeneration : D1-MSNs degenerate firstIndirect pathway involvement : D2-MSNs affected laterDifferential vulnerability : Striosomal MSNs more affected than matrixMutant Huntingtin (mHTT) The CAG repeat expansion in the HTT gene produces mutant [huntingtin protein](/proteins/huntingtin):
Polyglutamine expansion : >35 CAG repeats causes diseaseToxic gain-of-function : mHTT forms aggregatesLoss of normal function : Disrupted transcription, transportPathological Mechanisms
Transcriptional Dysregulation mHTT disrupts gene expression [3](https://doi.org/10.1016/j.neuron.2020.03.012):
CREB dysfunction : Impaired transcriptionREST dysregulation : Altered neuronal gene expressionPGC-1α suppression : Mitochondrial dysfunctionReduced neurotrophic factors : BDNF, GDNFExcitotoxicity Excessive glutamate signaling:
[NMDA receptor](/entities/nmda-receptor) overactivation : Calcium influxMetabotropic glutamate receptors : mGluR1/5 signalingAMPA receptor dysfunction : Altered synaptic transmissionMitochondrial Dysfunction
PGC-1α deficiency : Impaired biogenesisComplex I deficiency : Reduced ATP productionCalcium buffering : Impaired mitochondrial calcium handlingOxidative stress : [ROS](/entities/reactive-oxygen-species) accumulationProtein Aggregation
mHTT aggregates : Intraneuronal inclusion bodies[Autophagy](/entities/autophagy) impairment : Defective protein clearanceUbiquitin-proteasome dysfunction : Reduced degradationNeuropathological Findings
Striatal atrophy : 50-70% neuron loss in advanced HDNuclear inclusions : mHTT in neuronal nucleiDendritic spine loss : Reduced synaptic connectivityGliosis : Reactive astrocytosisTherapeutic Implications
Disease-Modifying Strategies
HTT-lowering therapies : ASOs, RNAi, CRISPRSmall molecule inhibitors : Targeting aggregationNeurotrophic factors : BDNF, GDNF deliveryCell replacement : Stem cell transplantationSymptomatic Treatments
Dopamine blockers : Tetrabenazine, deutetrabenazine Glutamate modulators : AmantadineDeep brain stimulation : Target STN, GPeGene therapy : AAV-based approachesSee Also
[Huntington's Disease](/diseases/huntington-disease)
[Striatum](/brain-regions/striatum)
[Basal Ganglia](/brain-regions/basal-ganglia)
[Medium Spiny Neurons](/cell-types/medium-spiny-neurons)
[D1 Dopamine Receptor](/proteins/drd1-protein)
[D2 Dopamine Receptor](/proteins/drd2-protein)
[Huntingtin Protein](/proteins/huntingtin)
[Excitotoxicity](/mechanisms/excitotoxicity)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
External Links
[Wikipedia](https://en.wikipedia.org/)
[NCBI Resources](https://www.ncbi.nlm.nih.gov/)
Show full description